Previous 10 | Next 10 |
FLORHAM PARK, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune ® T-cell activating technology, today announced publicatio...
FLORHAM PARK, N.J., May 18, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techno...
FLORHAM PARK, N.J., May 17, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology,...
PDS Biotechnology Corp (PDSB) Q1 2021 Earnings Conference Call May 13, 2021, 08:00 ET Company Participants Deanne Randolph - VP, Commericial Development & Head, IR Frank Bedu-Addo - President, CEO & Director Lauren Wood - Chief Medical Officer Seth Van Voorhees - CFO, Principal Financ...
PDS Biotechnology (PDSB): Q1 GAAP EPS of -$0.14 beats by $0.05.Cash balance as of March 31, 2021 was approximately $25.0 million.Shares +2.2%.Press Release For further details see: PDS Biotechnology EPS beats by $0.05
FLORHAM PARK, N.J., May 13, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating techno...
FLORHAM PARK, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating tec...
FLORHAM PARK, N.J., April 26, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune ® T-cell activating ...
Florham Park, NJ, April 19, 2021 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Company’s proprietary Versamune® T-cell activating technology,...
PDS Biotechnology Corporation (PDSB) Q4 2020 Earnings Conference Call March 18, 2021 08:00 A.M. ET Company Participants Deanne Randolph - IR Frank Bedu-Addo - CEO Lauren V. Wood - CMO Seth L. Van Voorhees - CFO Conference Call Participants Joseph Pantginis - H.C. Wainwright & Company Trev...
News, Short Squeeze, Breakout and More Instantly...
PDS Biotechnology Corporation Company Name:
PDSB Stock Symbol:
NASDAQ Market:
PDS Biotechnology Corporation Website:
PRINCETON, N.J., July 29, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectiou...
Majority of patients continue to be followed for survival with multiple patients approaching 3 years Median Overall Survival (mOS) remains at 30 months based on the most recent data cut with approximately six months of additional follow-up PRINCETON, N.J., June 12, 2024 (GLOBE NEW...